237 related articles for article (PubMed ID: 19549403)
1. [Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia].
Zhu BG; Qian SX; Hong M; Lu H; Wu HX; Zhang SJ; Qiu HX; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):760-4. PubMed ID: 19549403
[TBL] [Abstract][Full Text] [Related]
2. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
[TBL] [Abstract][Full Text] [Related]
3. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
Qu Q; Liu L; Zhang Y; Li X; Wu D
Leuk Res; 2015 Dec; 39(12):1353-9. PubMed ID: 26432074
[TBL] [Abstract][Full Text] [Related]
4. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
[TBL] [Abstract][Full Text] [Related]
5. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y
Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551
[TBL] [Abstract][Full Text] [Related]
6. Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia.
Liu L; Zhang Y; Jin Z; Zhang X; Zhao G; Si Y; Lin G; Ma A; Sun Y; Wang L; Wu D
Int J Hematol; 2014; 99(5):603-8. PubMed ID: 24623261
[TBL] [Abstract][Full Text] [Related]
7. [Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
Saito K
Rinsho Ketsueki; 1996 Aug; 37(8):651-3. PubMed ID: 8827872
[TBL] [Abstract][Full Text] [Related]
8. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
Xue SL; Cui HX; Zou JY; Xue MX; Tang XW; Zhang YM; Wu DP
Hematol Oncol; 2013 Dec; 31(4):206-12. PubMed ID: 23616245
[TBL] [Abstract][Full Text] [Related]
9. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
[TBL] [Abstract][Full Text] [Related]
11. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study.
Yamada K; Furusawa S; Saito K; Waga K; Koike T; Arimura H; Aoyagi A; Yamato H; Sakuma H; Tsunogake S
Leukemia; 1995 Jan; 9(1):10-4. PubMed ID: 7531259
[TBL] [Abstract][Full Text] [Related]
12. Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21).
Wang Y; Li W; Chen S; Qiu H; Sun A; Wu D
Leuk Res; 2011 May; 35(5):604-7. PubMed ID: 21130493
[TBL] [Abstract][Full Text] [Related]
13. Successful Cytoreduction with CAG (cytarabine, Aclarubicin and G-CSF) Therapy in Refractory Acute Myelogenous Leukemia before Allogeneic Stem Cell Transplantation.
Murayama T; Imoto S; Gomyo H; Mizuno I; Kajimoto K; Sugimoto T; Tobinai K; Koizumi T
Hematology; 2001; 6(6):381-5. PubMed ID: 27405694
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia.
Qian SX; Li JY; Tian T; Shen YF; Jiang YQ; Lu H; Wu HX; Zhang SJ; Xu W
Leuk Res; 2007 Oct; 31(10):1383-8. PubMed ID: 17420048
[TBL] [Abstract][Full Text] [Related]
15. Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China.
Zhang X; Li Y; Zhang Y; Chen X; Zhang C; Gao L; Kong P; Liu Y; Wen Q; Zeng Y; Wang Q; Su Y; Wang C; Wang S; Yuan Z; Gao L
Leuk Res; 2013 Jun; 37(6):657-64. PubMed ID: 23537708
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC].
Liu J; Jia JS; Gong LZ; Lu SY; Zhu HH; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):734-738. PubMed ID: 30369183
[No Abstract] [Full Text] [Related]
17. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
Minakata D; Fujiwara S; Ito S; Mashima K; Umino K; Nakano H; Kawasaki Y; Sugimoto M; Yamasaki R; Yamamoto C; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia].
Saito K; Furusawa S; Yamada K; Waga K; Aoyagi A; Koike T; Arimura H; Noguchi M; Yamato H; Sakuma H
Rinsho Ketsueki; 1995 Mar; 36(3):165-74. PubMed ID: 7540220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
